A comprehensive meta-analysis of 46,154 cancer patients demonstrates that concurrent statin use during immune checkpoint inhibitor therapy significantly improves overall survival and progression-free survival.

Reponex Pharmaceuticals prioritizes RNX-051 for colon adenomas and colon cancer, RNX-011 for peritonitis, and RNX-041 for IBD (pouchitis) due to strong clinical data.

A $11.4 million NIH grant funds a multi-center clinical trial to investigate the efficacy of nitric oxide in treating newborns with congenital diaphragmatic hernia (CDH).

Medicines Discovery Catapult has formed two major strategic partnerships with the Francis Crick Institute and University of Exeter to accelerate drug discovery and translational research across the UK.

University of Maryland researchers discovered that MRI-derived septal circumferential strain can detect early cardiac dysfunction in Duchenne muscular dystrophy patients before traditional markers appear.

Researchers have developed two new peptide compounds, GEP44 and KCEM1, that target weight loss with potentially fewer gastrointestinal side effects than current GLP-1 drugs.

MRIMath LLC's _i_ 2Contour, an AI-powered tool for glioblastoma mapping and measurement, has received FDA clearance, allowing its marketing to potential customers.

Sensorion has completed enrollment of the first cohort in its Phase I/II Audiogene trial, evaluating SENS-501 for OTOF gene-mediated hearing loss.

Immunic's ENSURE program, consisting of two Phase 3 trials evaluating vidofludimus calcium for relapsing multiple sclerosis (RMS), will proceed without modifications.

A Ministry of Health (MOH) committee investigated ethical concerns in a National Neuroscience Institute (NNI) study involving Parkinson's Disease, epilepsy, stroke and tardive dyskinesia patients.

Washington University School of Medicine initiates a pioneering trial of remternetug, a monoclonal antibody designed to prevent Alzheimer's disease by targeting amyloid-beta before symptom onset.

The European Medicines Agency (EMA) is reviewing semaglutide, the active ingredient in Ozempic and Wegovy, following reports of a potential link to non-arteritic anterior ischemic optic neuropathy (NAION).

A two-year trial by Amrita School of Ayurveda demonstrates the potential effectiveness of a cannabis-based polyherbal formulation called Formulation Femme in treating menstrual cramps.

Investigative journalists highlight concerns about the Alzheimer's drug donanemab, questioning clinical trial results and potential unethical behavior among FDA advisory members.

ASCO is urging the prioritization of health equity and the incorporation of social determinants of health (SDOH) data in pediatric cancer clinical trials.

Priority Health has completed its acquisition of Physicians Health Plan of Northern Indiana (PHPNI), expanding its footprint into Ohio and Indiana markets.

Six pharmaceutical facilities received category awards for innovation, operations, and social impact at the 2025 ISPE Europe Annual Conference, marking the 20th anniversary of the prestigious FOYA program.

Biosergen has completed enrollment of the first cohort in its BSG005 proof-of-concept trial, evaluating the drug as a rescue therapy for severe fungal infections.

A study by The Chinese University of Hong Kong reveals that performing endoscopy within 6 hours for acute upper gastrointestinal bleeding does not lower mortality or reduce the risk of further bleeding compared to endoscopy performed between 6 and 24 hours after consultation.

A comprehensive 12-year PURE study across 17 countries shows significant underutilization of secondary prevention medications for cardiovascular disease, with usage rates dropping to 31.3% in the final study visit.